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Background: The PPAR α and PPAR γ are the key messengers responsible for the translation of nutritional stimuli
into changes for the expression of genes, particularly genes involved in lipid metabolism. However, the associations
between PPAR α / γ polymorphisms and lipid serum levels in the general population were rarely studied, and the
conclusions were conflicting. The objective was to investigate the associations of the PPAR α and PPAR γ
polymorphisms with dyslipidemia.
Methods: 820 subjects were randomly selected from the Prevention of Multiple Metabolic Disorders and MS in
Jiangsu Province cohort populations. The logistic regression model was used to examine the association between
these polymorphisms and dyslipidemia. SNPstats was used to explore the haplotype association analyses.
Results: In the codominant and log-additive models, rs1800206, rs1805192 and rs3856806 were all associated with
dyslipidemia (P < 0.005). When the most common haplotype L-G (established by rs1800206, rs4253778) was treated
as the reference group, the V-G haplotype was associated with dyslipidemia (P < 0.001), higher TC and TG levels
(P < 0.01). Moreover, when compared to Pro-C haplotype (established by rs1805192, rs3856806), the Pro-T, Ala-C,
Ala-T haplotypes were associated with dyslipidemia (p < 0.001). A-T haplotype was associated with higher TC
levels, (p < 0.01), and the P-T, A-C, A-T haplotypes were associated with higher TG levels (p < 0.01).
Conclusions: PPAR α and PPAR γ polymorphisms and haplotypes may be the genetic risk factors for
dyslipidemia.
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Cardiovascular disease (CVD)represents the leading
cause of death in adults worldwide. Alterations in lipid
and lipoprotein metabolisms have been investigated as
important CVD risk factors [1]. It is well-known that
high LDL-cholesterol (LDL-c) and triglycerides (TG)
levels and low HDL-cholesterol (HDL-c) levels are
strong predictable factors for cardiovascular events [2].
Epidemiological data have indicated a continuous in-
crease in prevalence rate of dyslipidemia during the last
decades [1]. The exact cause of dyslipidemia is not
known. Genetics play an important role on lipid homeo-
stasis. The peroxisome proliferator-activated receptor
(PPAR) isotypesare ligand-activated nuclear transcription
factors, which have been identified that they play a* Correspondence: guozhirong28@163.com
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stated.critical physiological role as lipid sensors and regulators
of lipid metabolism [3,4]. The PPAR α and PPAR γ were
the key messengers responsible for the translation of nu-
tritional stimuli into changes for the expression of genes,
particularly genes involved in lipid metabolis [5]. PPAR
α and PPAR γ are encoded by distinct genes and have
specific tissue distribution.
PPAR α is mainly expressed in tissues with extensive
fatty acid catabolism and its activation leads to changes
in the transcription of multiple genes that regulate lipid
and lipoprotein metabolism including LPL, APOC3,
APOA1 and APOA5 [6,7]. Common variants of the
PPAR α have been described. Rs1800206 has been asso-
ciated with variation in lipid serum levels in Caucasian
and Indian populations [8,9]. Another polymorphism,
rs4253778 has also been found that it is associated with
variation in lipid serum levels [10]. But Mazzotti et al.
found that there were divergences on the associationThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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two studied population (São Paulo City and Cuiaba
City) [11,12].
PPAR γ is highly expressed in adipose tissue, where it
plays an indispensable role in the regulation of adipocyte
differentiation, lipid storage, glucose metabolism and the
transcriptional regulation of a number of genes involved
in these metabolic processes. Some of the key target
genes of PPAR γ include the fat-specific ap2 gene, LPL,
fatty acid transport, fatty acid binding protein, ABC-A1
[4,13]. The most studied of PPAR γ polymorphisms is
rs1805192 [14]. Rs3856806 variant has been found to be
associated with traits, which modulate the associations
observed with the rs1805192 [15]. At present, many
studies have reported that rs1805192 and rs3856806
polymorphisms were associated with obesity, insulin
sensitivity and Type 2 diabetes [16-18]. However, the
associations between rs1805192 or rs3856806 polymor-
phisms and lipid serum levels in the general popula-
tion were rarely studied, and the conclusions were
conflicting.
In the previous study, we have found that PPARα/γ
polymorphisms (rs1800206, rs3856806 and rs1805192)
were significantly associated with hypertriglyceridemia
[19]. Thus, the purpose of this study was to further in-
vestigate the association of the four variants at the PPAR
α (rs1800206, rs4253778 polymorphisms) and PPAR γ
(rs3856806 and rs1805192 polymorphisms) locus with
dyslipidemia. This study is the first to investigate the
role of PPAR α and PPAR γ polymorphisms with dyslip-
idemia in Chinese Han population. Moreover, this is the
first study that associated haplotypes of rs3856806 and
rs1805192 polymorphisms with dyslipidemia.
Results
Table 1 describes the characteristics of the studied popula-
tion. Dyslipidemia participants exhibited a significantly
higher mean age, BMI and WC than non-dyslipidemia
population. The four SNPs were within Hardy–Weinberg
equilibrium (P > 0.05). Linkage analysis showed there was
no significant linkage disequilibrium between rs1800206Table 1 Baseline characteristics of the studied samples
Variables Non- dyslipidemia (N = 628) Dyslipidemia (N =
Age (year)a 50.47 ± 9.51 48.65 ± 8.97
Maleb 204 (32.5) 66 (34.4)
Smoke N (%)b 160 (25.5) 45 (23.4)
Alcohol N (%)b 129 (20.5) 43 (22.4)
BMI (kg/m2)a 22.71 ± 3.14 23.77 ± 2.95
WC (cm)a 76.44 ± 8.67 81.50 ± 9.21
Note: means ± standard deviation for age, BMI, WC; BMI: body mass index; WC: waisand rs4253778 or between rs1805192 and rs3856806
polymorphisms (D’ < 0.75).
We further examined the potential associations be-
tween dyslipidemia and individual polymorphisms in
PPAR α and PPAR γ based on two models (codominant
and log-additive models; Table 2). In the codominant
model, when the LL genotype of rs1800206 was used as
the reference group, the LV genotype appeared to have a
higher risk for dyslipidemia (the adjusted OR 5.75, 95%
CI 3.91-8.46), whereas no association was observed to
the VV genotype (adjusted OR 2.38; 95% CI 0.43-13.31).
In the log-additive model, rs1800206 also appeared to be
associated with dyslipidemia, the adjusted OR (95% CI)
was 4.74(3.29-6.84). For the rs4253778 polymorphism,
when the CC genotype was used as the reference group,
the CG and GG genotypes were not associated with dys-
lipidemia (adjusted OR 0.95, 95% CI 0.63-1.43; adjusted
OR0.65, 95% CI 0.24-1.78, respectively). Similar result
was observed in the log-additive model(adjusted OR0.89,
95% CI 0.64-1.23). For the rs3856806 polymorphism,
when the CC genotype was used as the reference group,
the CT and TT genotypes were associated with dyslipid-
emia (adjusted OR 1.58, 95% CI 1.09-2.27; adjusted OR
2.23, 95% CI 1.28-3.90, respectively). In the log-additive
model, rs3856806 also appeared to be associated with
dyslipidemia (adjusted OR 1.53; 95% CI 1.19-1.97). For
the rs1805192 polymorphism, when the ProPro genotype
was used as the reference group, the ProAla and AlaAla
genotypes were associated with dyslipidemia (adjusted
OR 1.77, 95% CI 1.22-2.56; adjusted OR 2.96, 95% CI
1.70-5.14, respectively). Similar result was observed in
the log-additive model (adjusted OR 1.76, 95% CI
1.36-2.27).
Haplotype association analysis showed the associations
between V/G haplotype and dyslipidemia (OR = 5.20; 95%
CI = 3.46 ~ 7.82; p < 0.001; Table 3) and between V/G
haplotype and TC and TG levels when compared to L/G
haplotype (Difference = 0.4, 95% CI = 0.22 ~ 0.59, p < 0.01;
Difference = 1.63, 95% CI = 1.31 ~ 1.95, p < 0.01, respect-
ively; Table 2). In addition, when the most common haplo-
type P-C was treated as the reference group, the P-T, A-C,192) Total (N = 820) Statistical test values p- Value
50.05 ± 9.40 2.354 0.019
270 (32.9) 0.238 0.626
199 (24.3) 0.326 0.568
205 (25.0) 0.305 0.581
22.83 ± 3.12 -4.130 <0.001
77.00 ± 9.05 -6.978 <0.001
t circumference. aStudent’s t-test; bchi-square test.
Table 2 The association analysis between SNPs in PPAR-α/γ and dyslipidemia






Codominant LL 524 98 1.0 <0.001
LV 99 92 5.75 (3.91-8.46)
VV 5 2 2.38 (0.43-13.31)
Log additive - - - 4.74 (3.29-6.84) <0.001
rs4253778
Codominant CC 469 146 1.0 0.670
CG 133 41 0.95 (0.63-1.43)
GG 26 5 0.65 (0.24-1.78)
Log additive - - - 0.89 (0.64-1.23) 0.470
rs3856806
Codominant CC 343 75 1.0 0.005
CT 237 89 1.58 (1.09-2.27)
TT 48 28 2.23 (1.28-3.90)
Log additive - - - 1.53 (1.19-1.97) <0.001
rs1805192
Codominant ProPro 380 79 1.0 <0.001
ProAla 206 82 1.77 (1.22-2.56)
AlaAla 42 31 2.96 (1.70-5.14)
Log additive - - - 1.76 (1.36-2.27) <0.001
Adjusted for gender, age, smoke, alcohol, body mass index and waist circumference.
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1.90, 95% CI = 1.33 ~ 2.71, p < 0.001; OR = 2.17, 95% CI =
1.53 ~ 3.09, p < 0.001; OR = 2.06, 95% CI = 1.36 ~ 3.12, p <
0.001, respectively; Table 4). A-T haplotype was associated

















Adjusted for gender, age, smoking, alcohol consumption, BMI and waist circumferep < 0.01), and the P-T, A-C, A-T haplotypes were asso-
ciated with TG levels (Difference = 0.60, 95% CI = 0.32 -
0.88, p < 0.01; Difference = 0.87, 95% CI = 0.58 – 1.17,
p < 0.01; Difference = 0.94, 95% CI = 0.57 – 1.30, p < 0.01,
respectively) .morphisms and association with dyslipidemia, TC and
Frequency OR(95CI%) P-value
0.7477 1 -
0.1273 1.01 (0. 67 ~ 1.54) 0.94
0.1084 5.20 (3.46 ~ 7.82) <0.001
0.0166 2.31 (0.64 ~ 8.32) 0.20
Frequency Difference (95CI%) P-value
0.7487 0 -
0.1263 -0.1 (-0.26 ~ 0.05) 0.2
0.1074 0.4 (0.22 ~ 0.59) <0.001
0.0176 0.1 (-0.35 ~ 0.55) 0.65
Frequency Difference (95CI%) P-value
0.7476 0 -
0.1274 0.11 (-0.17 ~ 0.38) 0.45
0.1085 1.63 (1.31 ~ 1.95) <0.001
0.0165 0.43 (-0.58 ~ 1.44) 0.4
nce.
Table 4 Haplotypes of PPARγ rs1805192 and rs3856806 polymorphisms and association withdyslipidemia, TC and
TG levels
rs1805192 rs3856806 Frequency Difference (95CI%) P-value
Dyslipidemia Pro C 0.5393 1 -
Pro T 0.196 1.90 (1.33 ~ 2.71) <0.001
Ala C 0.1692 2.17 (1.53 ~ 3.09) <0.001
Ala T 0.0954 2.06 (1.36 ~ 3.12) <0.001
rs1805192 rs3856806 Frequency Difference (95CI%) P-value
Total cholesterol Pro C 0.5395 0 -
Pro T 0.1959 0.15 (0.00 ~ 0.30) 0.06
Ala C 0.1691 0.09 (-0.07 ~ 0.25) 0.29
Ala T 0.0956 0.29 (0.09 ~ 0.48) <0.001
rs1805192 rs3856806 Frequency Difference (95CI%) P-value
Triglyceride Pro C 0.539 0 -
Pro T 0.1963 0.6 (0.32 ~ 0.88) <0.001
Ala C 0.1695 0.87 (0.58 ~ 1.17) <0.001
Ala T 0.0951 0.94 (0.57 ~ 1.3) <0.001
Adjusted for gender, age, smoking, alcohol consumption, BMI and waist circumference.
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In this study, we aimed to investigate the association of
the four variants at the PPAR α (rs1800206, rs4253778
polymorphisms) and PPAR γ (rs3856806 and rs1805192
polymorphisms) locus with dyslipidemia.
In the single SNP association analysis, we found that
rs1800206 polymorphism was associated with dyslipid-
emia both in the codominant and log-additive models
(p < 0.001, Table 2). Rs1800206 polymorphisms has been
associated with changes in TG, total cholesterol, LDL- c,
HDL- c and APOA1 plasmacon centrations in many
populations such as Caucasian, Indian and African-
Americans populations [6,7,20,21], in part corroborating
our findings. Some previous studies found that the C allele
of rs4253778 was associated with increased total and
LDL-c, atherosclerosis progression and increased risk
for nonfatal myocardial infarction [10,22,23]. Although
it seems that the rs4253778 polymorphism has its influ-
ence on metabolism disturbances, we did not find asso-
ciations with dyslipidemia. Interestingly, Mazzotti et al.
found divergences on the association results regarding
the two polymorphisms between their two studied
population (São Paulo City andCuiaba City) [11,12].
For instance, while C allele of rs4253778 was associ-
ated with higher HDL-c and lower TG and VLDL
levels in the São Paulo population, the same allele was
associated with dyslipidemia in the Cuiaba population.
Mazzotti et al. [11] considered that the controversy
might be explained by the differential population strati-
fication within the two studied samples. These both
admixed populations presented different proportions of
participants with European and African ancestry, which
may account for the differences found between thestudies. Moreover, lifestyle and dietary habits differ
substantially between these populations. So we thought
the divergence on the association result regarding the
rs4253778 polymorphisms between our study and other
studies might be caused by the same reasons.
Haplotype association analysis showed the associations
between V/G haplotype and dyslipidemia (p < 0.001,
Table 3) and between V/G haplotype and TC and TG
levels (p < 0.01,Table 3) when compared to L/G haplo-
type (established by rs1800206 and rs4253778). These
results confirmed the associations found when individual
polymorphisms were analyzed. There is only one study
that associated haplotypes of these two polymorphisms
with lipid metabolism alterations. Mazzotti et al. [11]
found that in the São Paulo population, carriers of the
L/C haplotype were at increased risk for dyslipidemia
when compared to carriers of the most common L/G
haplotype (p = 0.021). In addition, carriers of the V/C
haplotype showed a tendency for increased risk for dys-
lipidemia, but it was not significant (p = 0.055). Unfortu-
nately, the definition for dyslipidemia in the São Paulo
population is different from ours. So the associated hap-
lotypes of these two polymorphisms with lipid metabol-
ism alterations should be thoroughly investigated in
future studies.
At present, many studies have reported that rs1805192
and rs3856806 polymorphisms were associated with
obesity, insulin sensitivity and Type 2 diabetes [16-18].
However, the associations between rs1805192 or rs3856806
polymorphisms and lipid serum levels in the general popula-
tion were rarely studied. Rs1805192 has been shown to be
associated with lower levels of serum total and non-HDL in
a Japanese population [24], lower LDL in T2D patients [25],
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studies [26]. In obesity individuals, this variant was associ-
ated with a trend of an increase in TG and significantly as-
sociated with the presence of combined hyperlipidaemia
[27]. In a group of 57 extremely obese men, this variant was
related with an increase in TG. In CAD patients, Zhou et al.
[28] found that rs3856806 polymorphism was associated
with a higher HDL cholesterol level and a lower blood glu-
cose level. Yilmaz-Aydogan [29] found that subjects with
the CT heterozygote genotype of the rs3856806 polymorph-
ism showed a higher serum triglyceride and VLDL-C
concentrations than those with the CC homozgotes in
the CHD patients with diabetes. Our study found that
rs1805192 and rs3856806 polymorphisms were associ-
ated with dyslipidemia both in the codominant and
log-additive models (p <0.01; Table 2), suggesting an
independent association between the two polymor-
phisms and dyslipidemia.
Haplotype analysis regarding rs1805192 and rs3856806
polymorphisms has also shown the associations with
dyslipidemia, TC and TG levels. When compared to car-
riers of the most common Pro/C haplotype, the Pro-T,
Ala-C, Ala-T haplotypes were associated with dyslipid-
emia (p < 0.001, Table 4). In addition, Ala-T haplotype
was associated with higher TC levels, (p < 0.01), and the
Pro-T, Ala-C, Ala-T haplotypes were associated with
higher TG levels (p < 0.01). So far, the haplotype analysis
regarding rs1805192 and rs3856806 polymorphisms for
dyslipidemia has not been reported yet.
Our study found that PPAR α and PPAR γ haplotypes
were associated with dyslipidemia. PPAR α controls the
expression of a wide range of hepatic genes encoding for
proteins involved in fatty acid catabolism and lipoprotein
metabolism. Its activation leads to changes in the tran-
scription of multiple genes that regulate lipid and lipo-
protein metabolism including LPL, APOC3, APOA1 and
APOA5. Vohl [9] and Sapone [30] et al. found that
rs1800206 had functional consequences on receptor ac-
tivity. PPAR γ plays an indispensible role in the regula-
tion of adipocyte differentiation, lipid storage, glucose
metabolism and the transcriptional regulation of a num-
ber of genes involved in these metabolic processes. The
key target genes of PPAR γ include the fat-specific ap2
gene, LPL, fatty acid transport, fatty acidbinding protein,
ABC-A1 and so on [6]. Deeb [31] found that the Ala
allele of rs1805192 showed decreased binding affinity
to the cognate promoter element and reduced ability
to transactivate responsive promoters. rs3856806 was
found to modulate the associations observed with the
codon 12 substitution [15]. We thought rs1800206,
rs1805192 and rs3856806 polymorphisms may influ-
ence the receptor activity, the ability to transactivate
responsive promoters and so on to regulate the key
target genes of PPAR α/γ which could influnce thelipid metabolism. But the specific biological mechan-
ism needs to be further studied.
One limitation of this study is that these findings may
not be generalizable to other populations. Large ethnically
matched studies would be necessary to know if such re-
ports are found in non-Chinese Han subjects. Second, the
information on some lifestyle and dietary habits which
might interact with PPAR α/γ genotypes or act as poten-
tial confounding factors was not available in our study.
In conclusion, our study has tested the association be-
tween four common polymorphisms within PPAR α/γ
gene and dyslipidemia based on single-locus and haplo-
type analyses. These results may help to evaluate their
polymorphisms and haplotypes as being characterized as
genetic risk factors for dyslipidemia. Independent replica-
tions in large sample sizes are needed to confirm the role
of the polymorphisms and haplotypes found in this study
and the risk factors such as the lifestyle and dietary habits
should be thoroughly investigated in future studies.
Materials and methods
Studied population
Participants were recruited from the Prevention of MetS
and Multi-metabolic Disorders in Jiangsu Province of
China Study [32], which was initiated from April of 1999
to June of 2004. Totaled 4,582 subjects for whom five
year follow-up data were obtained between March of
2006 and October of 2007. A total of 4,083 participants
(89.11%) received follow-up examination (the patients
who attended the follow-up examinations were similar
to those lost from the follow-up cohort in terms of age,
sex, smoking status, alcohol intake, family disease history
and metabolic variables; p >0.05). After excluding sub-
jects who had experienced stroke or exhibited cardiovas-
cular disease (n = 36, 11 of whom died), type 2 diabetes
(n = 289, 31 of whom died), missing data (n = 133) or
body mass index (BMI) < 18.5 kg/m2 (n = 27, 2 of whom
died), a total of 820 unrelated individual subjects (270
males, 550 females) were was selected from the
remaining 3,731 cases by using simple random sampling
and no individual was related. Subjects who were se-
lected were similar to those who were not selected in
terms of age, sex, smoking, alcohol, family disease his-
tory and metabolic variable. Blood samples of the 820
subjects were collected as a baseline and subjected to
genotype analyses. Lipids measured at follow-up were
used to examine the association with PPAR γ polymor-
phisms in the study. All the participants signed the in-
formed consent form. The study was approved by the
ethic committee of Soochow University.
Body measurements and laboratory methods
Participants in baseline and follow-up study surveys
both filled in a standard questionnaire and physical
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morning after at least 8 hours of fasting (used to detect
and establish cell library). The methods of investigation
at the follow up were same as those at baseline.
Cigarette smokers were those who reported smoking
cigarettes at least once a day for 1 year or more. Total
alcohol intake was expressed as the sum of milliliters of
alcohol per week from wine, beer and spirits. The an-
thropometric measurements included body weight and
waist circumferences (WC). BMI was calculated accord-
ing to the Quetelet equation. Plasma glucose was mea-
sured using the oxidase enzymatic method. Serum total
cholesterol (TC), HDL-c, and TG levels were measured
by enzymatically. LDL-c concen-trations were calculated
by using the Friedewald formula. The measurements were
conducted using an automatic biochemistry analyzer
(Hitachi Inc, Tokyo Japan). All analyses were performed
by the same lab. The methods of investigation at the fol-
low up were same as those at baseline.
Genotyping
Genomic DNA from participants was extracted from
EDTA-treated whole blood, using the DNA Blood Mini
Kit (Qiagen, Hilden, Germany) according to the manu-
facturer’s instructions. The qualities of isolated genomic
DNAs were checked using agarose gel electrophoresis
and the quantities determined using spectrophotometry.
Two approaches were employed to separate wildtype
and mutated alleles for the four SNPs. rs4253778 was
detected by plymerase chain reaction restriction frag-
ment length polymorphisms (PCR-RFLP), and the left
three SNPs were detected by Taqman fluorescence
probe. Restriction enzyme was used to identify and cut
specific sequence, then PCR was performed with the fol-
lowing primers: forward 5′- ACA ATC ACT CCT TAA
ATA TGG TGG-3′ and reverse 5′- AAG TAG GGA
CAG ACA GGA CCA GTA -3′. A 25 μl reaction mix-
ture was amplified by PCR, including DNA 20 ng,
0.05 μl Ex Taq DNA polymerase, 1 μl 10 × buffer, 0.8 μl
dTNP, 0.1 μl Forward primers, 0.1 μl reverse primers.
PCR conditions were as follows: initial denaturation for
3 min and 95°C, denaturation for 10 s and 95°C, annealingTable 5 Description for 4 SNPs of PPAR-α/γ







aMAF in the total group of this study.
MAF, minor allele frequency; SNP, single nucleotide polymorphism.for 30 s and 63°C, extension for 30 s and 72°C, 40 cycles.
ABI Prism7000 software and allelic discrimination proced-
ure was used for genotyping of fore-mentioned four SNPs.
A 25 μl reaction mixture including 1.25ul SNP Genotyp-
ing Assays(20×), 12.5 μl Genotying Master Mix(2×), 20 ng
DNA, and the conditions were as follows: initial denatur-
ation for 10 min and 95°C, denaturation for 15 s and
92°C, annealing and extension for 90 s and 60°C, 50
cycles. Table 5 provides detailed information on the se-
lected SNPs, including their features, allelic variants,
and the minor allele frequencies.Definitions
The criteria for lipid and lipoprotein levels were accord-
ing to the National Cholesterol Education Program [33].
Participants were diagnosed with dyslipidemia if they
had one or more of the following criteria: a plasma con-
centration of TC of ≥6.24 mmol/L, plasma concentration
of TG ≥ 2.26 mmol/L; plasma concentration of HDL-c
of <1.04 mmol/L for men or <1.30 mmol/L for women;
and a plasma concentration of LDL-c ≥4.14 mmol/L.Statistical analyses
The mean and standard deviation (SD) for continuous
variables normally distributed and percentage for cat-
egorical variable were calculated. Median and inter-
quartile range were calculated for continuous variables
that were not normally distributed. Continuous variables
were tested using the t-test and no-parametric test. Fre-
quencies of categorical variables were tested using the
chi-square test. Allele and genotype frequencies were
calculated for each polymorphism and the χ2test was
used to investigate deviation from Hardy –Weinberg
equilibrium. The logistic regression model was used to
examine the association between PPARα/γ polymor-
phisms and dyslipidemia. Odds-ratio (OR) and 95%
confidence interval (95% CI) were also calculated. Indi-
vidual polymorphism data analyses were performed
using SPSS 16.0. Estimation of linkage disequilibrium
between polymorphisms was performed using SHEsis
(http://analysis2.bio-x.cn/SHEsisMain.htm) software. HaplotypeExon/Intron Substitution MAFa
Intron_7 G > C 0.22
Exon_5 L > V 0.13
Exon_B Pro > Ala 0.26
Exon-6 C > T 0.15
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